Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Anecortave sterile
Anecortave Sterile, mL · 7 trials · 8 indications
| Arm | Type | Description |
|---|---|---|
| Anecortave Acetate | EXPERIMENTAL | Posterior juxtascleral injection in the study eye at 6 month intervals (Day 0, Month 6, Month 12, Month 18) |
| Anecortave Acetate Vehicle | PLACEBO_COMPARATOR | Posterior juxtascleral injection in the study eye at 6 month intervals (Day 0, Month 6, Month 12, Month 18) |
| 15 mg Anecortave Acetate, 3 month intervals | EXPERIMENTAL | Anecortave Acetate Sterile Suspension, 30 mg/mL, one 0.5 mL posterior juxtascleral depot injection at 3 month intervals (0, 3, 6, 9, 12, 15, 18 months). |
| 15 mg Anecortave Acetate, 6 month intervals | EXPERIMENTAL | Anecortave Acetate Sterile Suspension, 30 mg/mL, one 0.5 mL posterior juxtascleral depot injection at 6 month intervals (3, 9, 15, 21 months). |
| 30 mg Anecortave Acetate, 6 month intervals | EXPERIMENTAL | Anecortave Acetate Sterile Suspension, 60 mg/mL, one 0.5 mL posterior juxtascleral depot injection at 6 month intervals (3, 9, 15, 21 months). |
| Anecortave and Sham PDT | ACTIVE_COMPARATOR | - |
| PDT and Sham Anecortave Acetate | ACTIVE_COMPARATOR | - |
| 24 mg Anecortave Acetate | EXPERIMENTAL | Anecortave Acetate Sterile Suspension, 30 mg/mL, single depot administration of 0.8 mL in the study eye |
| 48 mg Anecortave Acetate | EXPERIMENTAL | Anecortave Acetate Sterile Suspension, 60 mg/mL, single depot administration of 0.8 mL in the study eye |
| 60 mg Anecortave Acetate | EXPERIMENTAL | Anecortave Acetate Sterile Suspension, 75 mg/mL, single depot administration of 0.8 mL in the study eye |
| Anecortave Acetate Depot | EXPERIMENTAL | - |
| Anecortave Acetate 3 mg Depot | EXPERIMENTAL | Single injection, anterior juxtascleral depot (AJD) |
| Anecortave Acetate 15 mg Depot | EXPERIMENTAL | Single injection, anterior juxtascleral depot (AJD) |
| Anecortave Acetate 30 mg Depot | EXPERIMENTAL | Single injection, anterior juxtascleral depot (AJD) |
| Name | Type | Description |
|---|---|---|
| Anecortave Acetate 15 mg sterile suspension | DRUG | 0.5 ml of 30 mg/ml administered as a posterior juxtascleral injection |
| Anecortave Acetate Vehicle | OTHER | Administered as a posterior juxtascleral injection |
| Anecortave Acetate Sterile Suspension, 30 mg/mL | DRUG | One 0.5 mL posterior juxtascleral depot injection at 3 or 6 month intervals |
| Anecortave Acetate Sterile Suspension, 60 mg/mL | DRUG | One 0.5 mL posterior juxtascleral depot injection at 6 month intervals |
| Photodynamic Therapy (PDT) | OTHER | - |
| Anecortave Acetate Sterile Suspension, 75 mg/mL | DRUG | Single administration by anterior juxtascleral depot |
| Anecortave Acetate Sterile Suspension, 6 mg/mL | DRUG | Single injection, anterior juxtascleral depot (AJD) |
| Anecortave Acetate Suspension Depot, 30 mg/mL | DRUG | One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye |
Inclusion Criteria: * Diagnosis of exudative AMD and a primary or recurrent subfoveal CNV lesion in the study eye. * Other protocol-defined inclusion criteria may apply. Exclusion Criteria: * Under 50 years. * Other protocol-defined exclusion criteria may apply.
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 7 | PHASE3 | Surabgene Lomparvovec, RGX-314, ABBV-6628 |
| Ocular Therapeutix Inc | OCUL | 3 | PHASE3 | OTX-TKI |
| 4D Molecular Therapeutics, Inc. | FDMT | 3 | PHASE3 | 4D-150 |
| Regeneron Pharmaceuticals, Inc. | REGN | 2 | PHASE3 | Aflibercept, Pozelimab, Cemdisiran |
| EyePoint, Inc. | EYPT | 2 | PHASE3 | EYP-1901 |
| Kodiak Sciences, Inc. | KOD | 1 | PHASE3 | Tarcocimab tedromer, Tabirafusp tedromer |
| Novartis AG Sponsored ADR | NVS | 4 | PHASE2 | Iptacopan, FWY003 |
| Outlook Therapeutics, Inc. | OTLK | 1 | PHASE3 | ONS-5010 |
| Adverum Biotechnologies, Inc. | ADVM | 4 | PHASE3 | Ixo-vec, ADVM-022 |
| Apellis Pharmaceuticals, Inc. | APLS | 1 | PHASE2 | APL-3007 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-81201887 |
| Alcon AG | ALC | 1 | PHASE1 | AR-14034 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE1 | SAR402663 |
Anecortave Sterile is an investigational small molecule eye medication developed by Alcon Inc. (ticker ALC). It is formulated as a sterile suspension and has been studied in Phase 2 clinical trials for ophthalmology conditions including open-angle glaucoma, ocular hypertension, eye diseases, and macular degeneration.
Anecortave Acetate Sterile Suspension has been studied in Phase 2 trials for open-angle glaucoma, ocular hypertension, steroid induced intraocular pressure elevation, eye diseases, and macular degeneration. It is an investigational therapy and is not approved for commercial use.
Anecortave Sterile is developed by Alcon Inc., which trades under the ticker ALC. Alcon is the sponsor of the clinical trial program evaluating the sterile suspension in patients with open-angle glaucoma, ocular hypertension, and related eye conditions.
Anecortave Sterile is in Phase 2 clinical development. All three of its listed trials are Phase 2 studies, and all have been completed. The program has enrolled a total of 1,061 participants across randomized, double-blind, controlled trials.
Anecortave Sterile has been evaluated in completed Phase 2 trials including NCT00691717 in open-angle glaucoma or ocular hypertension, NCT00451152 in open-angle glaucoma, NCT00320203 in open-angle glaucoma, and NCT00315640 in steroid induced intraocular pressure elevation. These studies enrolled 201, 89, 86, and 70 participants respectively.
Yes. Anecortave Sterile is also known as Anecortave Acetate Sterile Suspension, available in 6 mg/mL and 30 mg/mL strengths, as well as Anecortave Acetate 15 mg sterile suspension. These names refer to the same Alcon investigational product studied in Phase 2 eye disease trials.